TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Noxopharm Ltd. ( (AU:NOX) ) just unveiled an update.
Noxopharm Limited has achieved a significant milestone with the first administration of its novel drug candidate, SOF-SKN™, in the HERACLES clinical trial. This trial, conducted in Australia, aims to assess the safety and tolerability of SOF-SKN™ for autoimmune diseases, initially targeting cutaneous lupus erythematosus. The trial’s success could position Noxopharm as a key player in the growing global lupus market, valued at over US$3 billion, with potential applications for other autoimmune and inflammatory conditions.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company that focuses on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary technology platforms, Sofra™ and Chroma™, to enhance mRNA medicines and develop drugs for oncology and autoimmune diseases.
Average Trading Volume: 142,069
Technical Sentiment Signal: Sell
Current Market Cap: A$12.86M
For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.